What is Ena Respiratory?
Founded in 2020 and headquartered in Melbourne and Sydney, Australia, Ena Respiratory is dedicated to pioneering synthetic innate immunomodulators. The company's innovative approach targets the prevention of both viral and bacterial respiratory infections, addressing a critical unmet need in public health. Ena Respiratory's development trajectory suggests a company moving beyond its initial seed stages into a phase of scaling its research and development efforts.
How much funding has Ena Respiratory raised?
Ena Respiratory has raised a total of $59.6M across 4 funding rounds:
Series A
$7.6M
Other Financing Round
$24.6M
Other Financing Round
$5M
Series B
$22.4M
Series A (2020): $7.6M, investors not publicly disclosed
Other Financing Round (2021): $24.6M led by Brandon Capital, Uniseed, and Minderoo Foundation
Other Financing Round (2025): $5M supported by Flu Lab
Series B (2025): $22.4M featuring Uniseed, Flu Lab, Bill & Melinda Gates Foundation, and Brandon Capital
Key Investors in Ena Respiratory
Brandon Capital
Brandon Capital Partners specializes in seed and venture capital investments in the biomedical sector, focusing on life science companies that aim to improve patient outcomes. They provide support from early-stage seed investment to expansion capital, partnering with entrepreneurs to develop and commercialize innovative medical technologies.
Uniseed
Uniseed is a commercialization fund that invests in researchers, technologies, and businesses aimed at creating a positive impact. They provide seed capital, expert guidance, and access to a network of industry experts to help innovators progress and de-risk their projects.
Flu Lab
Flu Lab is dedicated to funding and advancing innovative solutions, including transformative vaccines, to address challenges related to influenza and improve overall health outcomes.
What's next for Ena Respiratory?
The substantial enterprise-level funding Ena Respiratory has attracted indicates a strong trajectory for growth and market penetration. This capital infusion is expected to accelerate the company's product development pipeline, potentially leading to clinical trials and eventual commercialization of its novel immunomodulatory therapies. The company's focus on preventing respiratory infections positions it strategically within the burgeoning biopharmaceutical sector, with future developments likely to attract further strategic investment and partnerships.
See full Ena Respiratory company page
